Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Addressing therapeutic options for KPC-3-producing ST307-Klebsiella pneumoniae: insights from in vitro evolution and mutant prevention strategies.

Antimicrobial agents and chemotherapy - 5 Aug 2026

Hernández-García Marta, Pérez-Viso Blanca, Nieto-Torres Marta, García-Castillo María, Michelena Malkoa, Martínez-Martínez Luis, Baquero Fernando, Ruiz-Garbajosa Patricia, Cantón Rafael

Abstract excerpt

Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam are key therapeutic options for infections caused by KPC-producing Klebsiella pneumoniae (KPC-Kp). Resistance may emerge during therapy, but knowledge on mutant prevention and collateral effects remains limited. Killing kinetics assays of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, and the combination of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azabicyclo Compounds
Share to Boronic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ceftazidime

Share to Imipenem

Share to Klebsiella Infections

Share to Meropenem

Share to Nucleosides

Share to Thienamycins

Source

Open in PubMed Open full text

Identifiers

PMID: 42383991
DOI: 10.1128/aac.00488-26
PMCID: PMC13436382

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Addressing therapeutic options for KPC-3-producing ST307-Klebsiella pneumoniae: insights from in vitro evolution and mutant prevention strategies.PMID 42383991Read ↗

Mutant prevention concentrations, in vitro resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible Klebsiella pneumoniae isolates showing ceftazidime/avibactam resistance.Semantic proximity Read ↗

Suboptimal ceftazidime-avibactam exposure drives sequential blaKPC mutations and intra-host coexistence of Klebsiella pneumoniae harboring distinct variants leading to persistent infection.Semantic proximity Read ↗

In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification.Semantic proximity Read ↗

Impact ofompk36genotype and KPC subtype on thein vitroactivity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producingK. pneumoniaeclinical isolatesSemantic proximity Read ↗

A large-scale surveillance revealed that KPC variants mediated ceftazidime-avibactam resistance in clinically isolated Klebsiella pneumoniae.Semantic proximity Read ↗

Stepwise KPC mutational accumulation confers high-level ceftazidime-avibactam resistance in ST11 carbapenem-resistant Klebsiella pneumoniae.Semantic proximity Read ↗

In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.Semantic proximity Read ↗

Increased bla KPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical IsolateSemantic proximity Read ↗

Genomic and molecular characterisation of a <i>Klebsiella pneumoniae</i> clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactamSemantic proximity Read ↗

Genomic and molecular characterisation of a KPC-producing Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactamSemantic proximity Read ↗

Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae –Producing KPC-31, a D179Y Variant of KPC-3Semantic proximity Read ↗

Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.